AP717A - Process for preparing sildenafil. - Google Patents
Process for preparing sildenafil. Download PDFInfo
- Publication number
- AP717A AP717A APAP/P/1997/001009A AP9701009A AP717A AP 717 A AP717 A AP 717A AP 9701009 A AP9701009 A AP 9701009A AP 717 A AP717 A AP 717A
- Authority
- AP
- ARIPO
- Prior art keywords
- group
- solvent
- sodium
- tertiary
- amine
- Prior art date
Links
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 title description 16
- 229960003310 sildenafil Drugs 0.000 title description 8
- 238000004519 manufacturing process Methods 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 90
- 238000000034 method Methods 0.000 claims abstract description 38
- 238000002360 preparation method Methods 0.000 claims abstract description 29
- 238000006243 chemical reaction Methods 0.000 claims description 47
- 239000002904 solvent Substances 0.000 claims description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 36
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 32
- 239000002585 base Substances 0.000 claims description 28
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 27
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 26
- -1 peroxide salt Chemical class 0.000 claims description 24
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 20
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 20
- 239000011541 reaction mixture Substances 0.000 claims description 20
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 18
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 claims description 18
- 150000001412 amines Chemical class 0.000 claims description 16
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 16
- RFFLAFLAYFXFSW-UHFFFAOYSA-N 1,2-dichlorobenzene Chemical compound ClC1=CC=CC=C1Cl RFFLAFLAYFXFSW-UHFFFAOYSA-N 0.000 claims description 15
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 13
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims description 12
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 12
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 11
- 229910052708 sodium Inorganic materials 0.000 claims description 11
- 239000011734 sodium Substances 0.000 claims description 11
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 9
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 claims description 8
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 8
- 229910052744 lithium Inorganic materials 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 7
- 229960001760 dimethyl sulfoxide Drugs 0.000 claims description 7
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 6
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 229910021529 ammonia Inorganic materials 0.000 claims description 6
- QVQLCTNNEUAWMS-UHFFFAOYSA-N barium oxide Chemical compound [Ba]=O QVQLCTNNEUAWMS-UHFFFAOYSA-N 0.000 claims description 6
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical class [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 6
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 6
- 229910052700 potassium Inorganic materials 0.000 claims description 6
- 239000011591 potassium Substances 0.000 claims description 6
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 6
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 6
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 claims description 6
- LZDKZFUFMNSQCJ-UHFFFAOYSA-N 1,2-diethoxyethane Chemical compound CCOCCOCC LZDKZFUFMNSQCJ-UHFFFAOYSA-N 0.000 claims description 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 5
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 claims description 5
- 239000008096 xylene Substances 0.000 claims description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 4
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims description 4
- 238000006386 neutralization reaction Methods 0.000 claims description 4
- OCJBOOLMMGQPQU-UHFFFAOYSA-N 1,4-dichlorobenzene Chemical compound ClC1=CC=C(Cl)C=C1 OCJBOOLMMGQPQU-UHFFFAOYSA-N 0.000 claims description 3
- 150000003973 alkyl amines Chemical class 0.000 claims description 3
- 229940117389 dichlorobenzene Drugs 0.000 claims description 3
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 claims description 3
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- 229910052684 Cerium Inorganic materials 0.000 claims description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 150000001342 alkaline earth metals Chemical class 0.000 claims description 2
- 239000004411 aluminium Substances 0.000 claims description 2
- 229910052782 aluminium Inorganic materials 0.000 claims description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 2
- QXNDZONIWRINJR-UHFFFAOYSA-N azocane Chemical compound C1CCCNCCC1 QXNDZONIWRINJR-UHFFFAOYSA-N 0.000 claims description 2
- 229910052788 barium Inorganic materials 0.000 claims description 2
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims description 2
- 229910052790 beryllium Inorganic materials 0.000 claims description 2
- ATBAMAFKBVZNFJ-UHFFFAOYSA-N beryllium atom Chemical compound [Be] ATBAMAFKBVZNFJ-UHFFFAOYSA-N 0.000 claims description 2
- 229910052793 cadmium Inorganic materials 0.000 claims description 2
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 claims description 2
- 229910052792 caesium Inorganic materials 0.000 claims description 2
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- ZMIGMASIKSOYAM-UHFFFAOYSA-N cerium Chemical compound [Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce] ZMIGMASIKSOYAM-UHFFFAOYSA-N 0.000 claims description 2
- 229910017052 cobalt Inorganic materials 0.000 claims description 2
- 239000010941 cobalt Substances 0.000 claims description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 239000010949 copper Substances 0.000 claims description 2
- 229910052738 indium Inorganic materials 0.000 claims description 2
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 claims description 2
- 229910052753 mercury Inorganic materials 0.000 claims description 2
- 159000000001 potassium salts Chemical class 0.000 claims description 2
- 229910052701 rubidium Inorganic materials 0.000 claims description 2
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 claims description 2
- 229910052709 silver Inorganic materials 0.000 claims description 2
- 239000004332 silver Substances 0.000 claims description 2
- 239000012312 sodium hydride Substances 0.000 claims description 2
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 2
- 229910052712 strontium Inorganic materials 0.000 claims description 2
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 claims description 2
- 229910052716 thallium Inorganic materials 0.000 claims description 2
- BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 claims description 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims description 2
- 229910052719 titanium Inorganic materials 0.000 claims description 2
- 239000010936 titanium Substances 0.000 claims description 2
- 150000003852 triazoles Chemical class 0.000 claims description 2
- JABYJIQOLGWMQW-UHFFFAOYSA-N undec-4-ene Chemical compound CCCCCCC=CCCC JABYJIQOLGWMQW-UHFFFAOYSA-N 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 229910052726 zirconium Inorganic materials 0.000 claims description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 3
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 claims 2
- 150000004703 alkoxides Chemical class 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 150000004678 hydrides Chemical class 0.000 claims 1
- KPADFPAILITQBG-UHFFFAOYSA-N non-4-ene Chemical compound CCCCC=CCCC KPADFPAILITQBG-UHFFFAOYSA-N 0.000 claims 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 34
- 238000004458 analytical method Methods 0.000 description 33
- 238000004809 thin layer chromatography Methods 0.000 description 33
- 239000000243 solution Substances 0.000 description 30
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 239000012043 crude product Substances 0.000 description 20
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 238000010992 reflux Methods 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 13
- 238000001914 filtration Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 239000000463 material Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- 239000012258 stirred mixture Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- JVVRJMXHNUAPHW-UHFFFAOYSA-N 1h-pyrazol-5-amine Chemical compound NC=1C=CNN=1 JVVRJMXHNUAPHW-UHFFFAOYSA-N 0.000 description 5
- IOHPVZBSOKLVMN-UHFFFAOYSA-N 2-(2-phenylethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1CCC1=CC=CC=C1 IOHPVZBSOKLVMN-UHFFFAOYSA-N 0.000 description 5
- 239000002841 Lewis acid Substances 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 150000007517 lewis acids Chemical class 0.000 description 5
- 239000001117 sulphuric acid Substances 0.000 description 5
- 235000011149 sulphuric acid Nutrition 0.000 description 5
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000013074 reference sample Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 4
- XDZMPRGFOOFSBL-UHFFFAOYSA-N 2-ethoxybenzoic acid Chemical compound CCOC1=CC=CC=C1C(O)=O XDZMPRGFOOFSBL-UHFFFAOYSA-N 0.000 description 3
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 3
- 239000002808 molecular sieve Substances 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 3
- XTHPWXDJESJLNJ-UHFFFAOYSA-N sulfurochloridic acid Chemical compound OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 3
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 3
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
- VXEGSRKPIUDPQT-UHFFFAOYSA-N 4-[4-(4-methoxyphenyl)piperazin-1-yl]aniline Chemical compound C1=CC(OC)=CC=C1N1CCN(C=2C=CC(N)=CC=2)CC1 VXEGSRKPIUDPQT-UHFFFAOYSA-N 0.000 description 2
- 229910015900 BF3 Inorganic materials 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 2
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- PQLAYKMGZDUDLQ-UHFFFAOYSA-K aluminium bromide Chemical compound Br[Al](Br)Br PQLAYKMGZDUDLQ-UHFFFAOYSA-K 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000012024 dehydrating agents Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
- 238000010915 one-step procedure Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000005049 silicon tetrachloride Substances 0.000 description 2
- UVMAXIWRKVCCRS-UHFFFAOYSA-N sodium;cyclohexylazanide Chemical class [Na+].[NH-]C1CCCCC1 UVMAXIWRKVCCRS-UHFFFAOYSA-N 0.000 description 2
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 2
- VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 2
- 239000011592 zinc chloride Substances 0.000 description 2
- 235000005074 zinc chloride Nutrition 0.000 description 2
- BHHYHSUAOQUXJK-UHFFFAOYSA-L zinc fluoride Chemical compound F[Zn]F BHHYHSUAOQUXJK-UHFFFAOYSA-L 0.000 description 2
- UAYWVJHJZHQCIE-UHFFFAOYSA-L zinc iodide Chemical compound I[Zn]I UAYWVJHJZHQCIE-UHFFFAOYSA-L 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- OGFAWKRXZLGJSK-UHFFFAOYSA-N 1-(2,4-dihydroxyphenyl)-2-(4-nitrophenyl)ethanone Chemical compound OC1=CC(O)=CC=C1C(=O)CC1=CC=C([N+]([O-])=O)C=C1 OGFAWKRXZLGJSK-UHFFFAOYSA-N 0.000 description 1
- VTBOTOBFGSVRMA-UHFFFAOYSA-N 1-Methylcyclohexanol Chemical compound CC1(O)CCCCC1 VTBOTOBFGSVRMA-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical class CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- MDKAAWDKKBFSTK-UHFFFAOYSA-N 2-ethoxybenzoyl chloride Chemical compound CCOC1=CC=CC=C1C(Cl)=O MDKAAWDKKBFSTK-UHFFFAOYSA-N 0.000 description 1
- IBHHTADZYDLHPM-UHFFFAOYSA-N 2-methylnonan-4-ol Chemical compound CCCCCC(O)CC(C)C IBHHTADZYDLHPM-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- PZMXDLWWQHYXGY-UHFFFAOYSA-N 4-amino-1-methyl-3-propylpyrazole-5-carboxamide Chemical compound CCCC1=NN(C)C(C(N)=O)=C1N PZMXDLWWQHYXGY-UHFFFAOYSA-N 0.000 description 1
- UHNRCKXZRULNSC-UHFFFAOYSA-N 5-chlorosulfonyl-2-ethoxybenzoic acid Chemical compound CCOC1=CC=C(S(Cl)(=O)=O)C=C1C(O)=O UHNRCKXZRULNSC-UHFFFAOYSA-N 0.000 description 1
- RVDLHGSZWAELAU-UHFFFAOYSA-N 5-tert-butylthiophene-2-carbonyl chloride Chemical compound CC(C)(C)C1=CC=C(C(Cl)=O)S1 RVDLHGSZWAELAU-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 238000006418 Brown reaction Methods 0.000 description 1
- FIPWRIJSWJWJAI-UHFFFAOYSA-N Butyl carbitol 6-propylpiperonyl ether Chemical compound C1=C(CCC)C(COCCOCCOCCCC)=CC2=C1OCO2 FIPWRIJSWJWJAI-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 241000400611 Eucalyptus deanei Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- 229910021623 Tin(IV) bromide Inorganic materials 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- 229910000329 aluminium sulfate Inorganic materials 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 159000000009 barium salts Chemical class 0.000 description 1
- GYIWFHXWLCXGQO-UHFFFAOYSA-N barium(2+);ethanolate Chemical compound [Ba+2].CC[O-].CC[O-] GYIWFHXWLCXGQO-UHFFFAOYSA-N 0.000 description 1
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- CRCKGIUJMFFISH-UHFFFAOYSA-N copper;ethanolate Chemical compound [Cu+2].CC[O-].CC[O-] CRCKGIUJMFFISH-UHFFFAOYSA-N 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- FJBFPHVGVWTDIP-UHFFFAOYSA-N dibromomethane Chemical compound BrCBr FJBFPHVGVWTDIP-UHFFFAOYSA-N 0.000 description 1
- 239000002027 dichloromethane extract Substances 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 208000006278 hypochromic anemia Diseases 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 229960002523 mercuric chloride Drugs 0.000 description 1
- 229960003671 mercuric iodide Drugs 0.000 description 1
- NGYIMTKLQULBOO-UHFFFAOYSA-L mercury dibromide Chemical compound Br[Hg]Br NGYIMTKLQULBOO-UHFFFAOYSA-L 0.000 description 1
- LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 description 1
- YFDLHELOZYVNJE-UHFFFAOYSA-L mercury diiodide Chemical compound I[Hg]I YFDLHELOZYVNJE-UHFFFAOYSA-L 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- DVSCRPJCTIOVGO-UHFFFAOYSA-N methyl 2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylbenzoate Chemical compound C1=C(C(=O)OC)C(OCC)=CC=C1S(=O)(=O)N1CCN(C)CC1 DVSCRPJCTIOVGO-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- FTQWRYSLUYAIRQ-UHFFFAOYSA-N n-[(octadecanoylamino)methyl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCNC(=O)CCCCCCCCCCCCCCCCC FTQWRYSLUYAIRQ-UHFFFAOYSA-N 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- AIFMYMZGQVTROK-UHFFFAOYSA-N silicon tetrabromide Chemical compound Br[Si](Br)(Br)Br AIFMYMZGQVTROK-UHFFFAOYSA-N 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- GYBMSOFSBPZKCX-UHFFFAOYSA-N sodium;ethanol;ethanolate Chemical compound [Na+].CCO.CC[O-] GYBMSOFSBPZKCX-UHFFFAOYSA-N 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- LTSUHJWLSNQKIP-UHFFFAOYSA-J tin(iv) bromide Chemical compound Br[Sn](Br)(Br)Br LTSUHJWLSNQKIP-UHFFFAOYSA-J 0.000 description 1
- JMXKSZRRTHPKDL-UHFFFAOYSA-N titanium ethoxide Chemical compound [Ti+4].CC[O-].CC[O-].CC[O-].CC[O-] JMXKSZRRTHPKDL-UHFFFAOYSA-N 0.000 description 1
- UBZYKBZMAMTNKW-UHFFFAOYSA-J titanium tetrabromide Chemical compound Br[Ti](Br)(Br)Br UBZYKBZMAMTNKW-UHFFFAOYSA-J 0.000 description 1
- XROWMBWRMNHXMF-UHFFFAOYSA-J titanium tetrafluoride Chemical compound [F-].[F-].[F-].[F-].[Ti+4] XROWMBWRMNHXMF-UHFFFAOYSA-J 0.000 description 1
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- MDDPTCUZZASZIQ-UHFFFAOYSA-N tris[(2-methylpropan-2-yl)oxy]alumane Chemical compound [Al+3].CC(C)(C)[O-].CC(C)(C)[O-].CC(C)(C)[O-] MDDPTCUZZASZIQ-UHFFFAOYSA-N 0.000 description 1
- 229940102001 zinc bromide Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
A process for the preparation or a compound or formula (1). which comprises cyclisation of a compound of formula (II):
Description
PROCESS FOR PREPARING SILDENAFIL
The invention relates to a process for the preparation of the compound of formula (I):
/ \
SO,N NCH. \_/ known as 5-[2-ethoxy-5-(4-methylpiperazin-1 -y!sulphonyl)phenyi]-1 -methyl-3-npropyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one or sildenafil, and also to intermediates used therein. Sildenafil, which was originally disclosed in EP-A0463756, has been found to be particularly useful in the treatment of, inter alia, male erectile dysfunction: see WO-A-94/28902.
More specifically, the invention concerns a process for the preparation of sildenafil which is more efficient than that disclosed in EP-A-0463756 and which, ΐ-, 15 surprisingly, can provide directly sildenafil of clinical quality standard, thus obviating the need for subsequent purification steps. In this context, sildenafil of clinical quality standard means material of sufficient purity for administration to humans.
The key step in the over-all process involves the ring-closure of the 20 immediate precursor to sildenafil, i.e. the bis-amide of formula (II):
AP/P/ 9 7 / 0 1 0 0 9
AP. ο Ο 7 1 7
/7¼ •Λ
Thus the invention provides a process for the preparation of a compound of formula (I) which comprises cyclisation of a compound of formula (II).
In a preferred embodiment, the cyclisation is carried out in the presence of a base, preferably in a solvent, optional ly in the presence of hydrogen peroxide or a peroxide salt, and is followed, where necessary, by neutralisation of the reaction mixture.
A suitable base may be selected from the group consisting of a metal salt of a CrC12 alkanol , a C3-C12 cycloalkanol, a (C3-C8 cycloalkyOC^Cg alkanol, ammonia, a CrC12 alkylamine, a di(CrC12 alkyl)amine, a C3-C8 cycloalkyfamine, a N-(C3-C8 cycloalkylJ-N-iC^C^ alkyl)amine, a di(C3-C8 cycloalkyl)amine, a (C3-C3 (JT 15 cycloalkyOCvCg alkylamine, a N-(C3-C8 cycloalkyl)C.|-C6 alkyl-N-(CrC12 alkyl)amine, a N-(C3-C8 cycloalkyOC^Cg aikyl-N-(C3-C8 cycloalkyl)amine, a di[(C3C8 cycloalkyQC^Cg alkyljamine and a heterocyclic amine selected from the group consisting of imidazole, triazole, pyrrolidine, piperidine, heptamethyleneimine, morpholine, thiomorpholine and a 1-(CrC4 alkyl)piperazine; a metal hydride, fluoride, hydroxide, oxide, carbonate and bicarbonate; wherein the metal is selected from the group consisting of lithium, sodium, potassium, rubidium, cesium, beryllium, magnesium, calcium, strontium, barium, aluminium, indium, thallium, titanium, zirconium, cobalt, copper, silver, zinc, cadmium, mercury and cerium; and a C7-C12 bicyclic amidine.
Preferably the base is selected from the group consisting of an alkali or
AP/P/ 9 7 / 0 1 0 09
AP. ο ΰ 7 1 7
-3alkaline earth metal salt of a CrC12 alkanol, a C3-C12 cycioalkanol and a (C3-C3 cycloalkyl) Ο·,-Ο6 alkanol; an alkali metal salt of ammonia, a N-(secondary or tertiary C3-C6 aikyl)-N-(primary, secondary or tertiary C3-C5 alkyi)amine, a C3-C8 cycloalkylamine, a N-(C3-CS cycloalkyl)-N-(primary, secondary or tertiary C3-C5 alkyl)amine, a di(C3-C8 cyc!oalkyl)amine and 1-methylpiperazine; and an alkali or alkaline earth metal hydride, hydroxide, oxide, carbonate and bicarbonate; 1,5diazabicyc!o[4.3.0]non-5-ene and 1,8-diazabicyclo[5.4.0]undec-7-ene.
A suitable solvent may be selected from the group consisting of a CrC12 10 alkanol, a C3-C12 cycioalkanol, a (C3-Cs cycIoaIkyl)CrC6 alkanol, a C3-Cg alkanone, a C4-C10 cycloalkanone, a C5-C12 alkyl ether, 1,2-dimethoxyethane, 1,2diethoxyethane, diglyme, tetrahydrofuran, 1,4-dioxan, benzene, toluene, xylene, chlorobenzene, dichlorobenzene, acetonitrile, dimethyl sulphoxide, sulphoiane, dimethylformamide, dimethylacetamide, N-methylpyrrolidin-2-one, pyrrolidin-215 one, pyridine and water, and mixtures thereof.
Preferably the solvent is selected from the group consisting of ethanol, 2propanoi, a secondary or tertiary C4-C12 alkanol, a C3-C12 cycioalkanol, a tertiary C4-C12 cycioalkanol, a secondary or tertiary (C3-C7 cycloalkyl)C2-C6 alkanol, a C3C9 alkanone, 1,2-dimethoxyethane, 1,2-diethoxyethane, diglyme, tetrahydrofuran,
1,4-dioxan, toluene, xylene, chlorobenzene, 1,2-dichlorobenzene, acetonitrile, dimethyl sulphoxide, sulphoiane, dimethylformamide, N-methyipyrrolidin-2-one pyridine and water, and mixtures thereof.
Further preferred features are that the quantity of base employed is from 1.0 to 5.0 molecular equivalents and that the reaction is carried out at from 50 to
170°C for from 3 to 170 hours.
In a more preferred process the base is selected from the group consistina of the lithium, sodium and potassium salts of a CrC12 alkanol, a C4-C«2 cycioalkanol, ammonia, cyclohexyiamine and 1-methylpiperazine; the hydride salts of lithium, sodium and potassium; cesium carbonate; and barium oxide; the solvent is selected from the group consisting of ethanol, a tertiary C4-C10 alcohol, a tertiary
AP/P/ 9 7 / 0 1 0 09
AP. Ο Ο 71 7
-4Cs-C8 cycloalkanol, tetrahydrofuran, 1,4-dioxan and acetonitrile, the reaction is carried out at from 60 to 105°C and the quantity of base employed is from 1.1 to 2.0 molecular equivalents.
Even more preferred is a process wherein the base is selected from the group consisting of the C-|-C12 alkoxide and hydride salts of lithium, sodium and potassium, sodamide, sodium cyclohexylamide and cesium carbonate; the solvent is selected from the group consisting of ethanol, t-butanol, t-amyl alcohol, 1methylcyclohexanol, tetrahydrofuran and 1,4-dioxan; and the reaction is conducted for from 3 to 60 hours.
A particularly preferred process is that wherein the base is selected from the group consisting of sodium ethoxide, sodium t-butoxide, potassium t-butoxide and sodium hydride; and the solvent is selected from the group consisting of ethanol, tbutanol, t-amyl alcohol and tetrahydrofuran.
In the above definitions, unless otherwise stated, an alkyi chain or cycloalkyl ring may branched or unbranched.
The compound of formula (I) may be isolated and purified by conventional techniques. For example, when (I) is produced in the form of a salt, by neutralisation of the optionally prediluted reaction mixture, followed by collection of the product by filtration/extraction and optional crystallisation thereof.
Alternatively, the compound of formula (I) may be conveniently isolated and/or purified by standard chromatographic procedures.
The compound of formula (II) required for the preparation of the compound 25 of formula (I) may be obtained by'the route depicted in the following reaction scheme using conventional procedures.
AP/P/ 9 7 / 0 1 0 09
AP.00717
-5SCHEME
I (VII) (VI)
AP/P/ 9 7 / 0 1 0 09
(ll)
AP. Ο Ο 717
-6-.....
Thus the compound of formula (IV) may be prepared by chloros.ulphonylation of 2-ethoxybenzoic acid, i.e. the compound of formula (III). Typically, (III) is added to an ice-cooled mixture of about 1 mol. equiv. of thionyl chloride and about 4 mol.
equivs. of chlorosulphonic acid, whilst maintaining the reaction temperature below 25°C; the reaction is then allowed to continue at room temperature until complete.
Conversion of (IV) to the compound of formula (V) is achieved by Nsulphonylation of 1-methylpiperazine and may be conducted in a one-step or twostep procedure. In a one-step procedure, about 2.3 mol. equivs. of 110 methylpiperazine are added to an aqueous suspension of (IV) at about 10°C, whilst maintaining the reaction temperature below 20°C; the temperature of the resulting reaction mixture is then held at about 10°C. Alternatively, the quantity of 1-methylpiperazine can be reduced to about 1.1 mol. equiv. by employing about 1 mol. equiv. of sodium hydroxide as auxiliary base. In a two-step procedure, a solution of (IV) in a suitable solvent, e.g. acetone, is added to a mixture of about a 10% excess of 1-methylpiperazine and about a 10% excess of a suitable acid acceptor, e.g. a tertiary base such as triethylamine, whilst maintaining the reaction temperature below 20°C. When triethylamine is employed as auxiliary base, an intermediate hydrochloride-triethylamine double salt of (V), identified as the compound of formula (VA), is isolated. This salt may be transformed to (V) by treatment with water.
A convenient alternative route to (V) is to employ a ΟΓΟ4 alkyl 2ethoxybenzoate (obtained by conventional esterification of (III)) as the chlorosulphonylation substrate, followed by treatment of the resulting suiphonyl chloride with 1-methylpiperazine as described above, then subsequent standard hydrolysis of the ester group. Other synthetic options for obtaining (V) from salicylic acid and its derivatives will be apparent to the person skilled in the art.
Coupling of (V) with the compound of formula (VII) may be achieved by any of the plethora of amide bond-forming reactions well known to those skilled in the
AP/P/ 9 7 / 0 1 0 09
0 7 1 7
-/art. For example, the carboxylic acid function of (V) is first of all activated using about a 5% excess of a reagent such as N,N’- carbonyldiimidazole in a suitable solvent, e.g. ethyl acetate, at from about room temperature to about 80°C, followed by reaction of the intermediate imidazolide with (VII) at from about 20 to about 60°C.
The aminopyrazole (VII) is obtainable by conventional reduction of the corresponding nitropyrazoie (Vi), e.g. using palladium-catalysed hydrogenation in a suitable solvent such as ethyl acetate. The resulting solution of (VII) may be used directly, after filtration, in the coupling reaction with (V).
The cyclisation reaction of (il) to provide the compound of formula (I) has if.
been achieved in yields of up to 95%. Thus the over-all yield of (I) based on the benzoic acid derivative (III) as starting material, depending on whether the onestep or two-step sulphonylation procedure is used, can be as high as 51.7% or
47.8% respectively. This compares very favourably with the process disclosed in
EP-A-0463756 in which the over-all yield of (I) from 2-ethoxybenzoyl chloride (and thus from (III) also, assuming that the acid chloride derivative can be generated quantitatively therefrom) is 27.6%. In an alternative comparison, the over-all yield of (I) based on the nitropyrazoie (VI) can be as high as 85.2% in the presently disclosed process whilst, in the process disclosed in EP-A-0463756, the over-all yield of (I) from (VI) is 23.1%.
O Clearly then, the alternative process to (I) disclosed hereinbefore can be considerably more efficient and advantageous than that previously disclosed, and the intermediates of formulae (li), (V) and (VA) also form part of the invention.
Alternatively, the cyclisation of a compound of formula (11) to a compound of formula (I) may be conducted under neutral or acidic conditions.
Under neutral conditions, the compound of formula (II) is heated, optionally in the presence of a solvent and/or optionally in the presence of a dehycratina agent and/or mechanical water-removal system, e.g. a Dean-Stark apparatus.
AP/P/ 9 7 / 0 1 0 09
AP. Ο Ο 717
-8Α suitable solvent may be selected from the group consisting of 1,2dichlorobenzene, dimethyl sulphoxide, sulpholane, N-methylpyrroiidin-2-one and pyrrolidin-2-one, and mixtures thereof.
Preferably the solvent is 1,2-dichlorobenzene, sulpholane or Nmethylpyrrolidin-2-one.
A suitable dehydrating agent may be selected from the group consisting of anhydrous potassium carbonate, anhydrous sodium carbonate, anhydrous magnesium sulphate, anhydrous sodium sulphate, phosphorus pentoxide and molecular sieves.
Preferably the dehydrating agent is molecular sieves.
Preferably also, the'reaction is carried out at from 180 to 220°C for from 0.5 to 72 hours.
Under acidic conditions, the cyclisation is carried out by reaction of a 15 compound of formula (II) with a protic acid or Lewis acid, optionally in the presence of a solvent.
A suitable protic acid may be selected from the group consisting of an inorganic acid, an organo-sulphonic acid, an organo-phosphonic acid and an organo-carboxylic acid.
Preferably the protic acid is concentrated sulphuric acid, phosphoric acid or β-toluenesuiphonic acid.
T A A suitable Lewis acid may be selected from the group consisting of boron trifluoride, boron trichloride, boron tribromide, aluminium chloride, aluminium bromide, silicon tetrachloride, silicon tetrabromide, stannic chloride, stannic bromide, phosphorus pentacnioride, phosphorus pentabromide, titanium tetrafluoride, titanium tetrachloride, titanium tetrabromide, ferric chloride, zinc fluoride, zinc chloride, zinc bromide, zinc iodide, mercuric chloride, mercuric bromide and mercuric iodide.
Preferably the Lewis acid is boron trifluoride, aiuminium chloride, silicon tetrachloride, stannic chloride, titanium tetrachloride, ferric chloride or zinc chloride.
AP/P/ 9 7 / 0 1 0 09
AP.00717
-9A suitable solvent may be selected from the group consisting of a CA-C12 alkane, a C5-C8 cycloalkane, a aikanoic acid, a CrC4 alkanol, a C3-Co alkanone, a C5-C12 alkyl ether, 1,2-dimethoxyethane, 1,2-diethoxyethane, diglyme, tetrahydrofuran, 1,4-dioxan, benzene, toluene, xylene, chlorobenzene, dichlorobenzene, nitrobenzene, dichloromethane, dibromomethane, 1,2dichloroethane, acetonitrile, dimethyl sulphoxide, sulpholane, dimethylformamide, dimethylacetamide, N-methylpyrrolidin-2-one and pyrrolidin-2-one, and mixtures thereof.
Preferably the solvent is glacial acetic acid, tetrahydrofuran, 1,4-dioxan or chlorobenzene.
.··.·» · Preferably also, the reaction is carried out at from 65 to 210°C for from 6 to
300 hours.
The syntheses of the compound of formula (I) and the intermediates thereto are described in the following Examples and Preparations. In cases where the compound of formula (I) was not isolated and (if necessary) purified, the yields thereof were determined, and reaction mixtures analysed, by quantitative thin layer chromatography (TLC), using Merck silica gel 60 plates and tolueneimethylated spirit:0880 aqueous ammonia mixtures as solvent systems,
-¾ and/or high performance liquid chromatography (HPLC), using Gilson equipment with a 15 cm reverse phase C18 column and triethylamineiphosphoric acid buffer in aqueous acetonitrile:methanol mixtures as mobile phases.
1H Nuclear magnetic resonance (NMR) spectra were recorded using a
Varian Unity 300 spectrometer and were in all cases consistent with the proposed structures. Characteristic chemical shifts (δ) are given in parts-per-million downfield from tetramethyisilane using conventional abbreviations for desianation of significant peaks: e.g. s, singlet: d, doublet; t, triplet; q, quartet; h, hextet; m, multiplet; br, broad.
Room temperature means 20-25°C.
AP/P/ 9 7 / 0 1 0 09
AP. Ο Ο 71 7
-10TITLE COMPOUND
5-[2-Ethoxy-5-(4-methylpiperazin-1-ylsulphonyl)phenyl1-1-methyl-3-n-propyl-1.65 dihydro-7H-pyrazoloi4.3-d1pyrimidin-7-one
EXAMPLE 1
Potassium t-butoxide (3.37 g, 0.030 mol) was added to a stirred suspension of the title compound of Preparation 4 (12.32 g, 0.025 mol) in t-butanol (61 ml) and the resulting mixture heated under reflux for 8 hours, then allowed to cool to room temperature. Water (62.5 mi) was added and then the resulting solution filtered into a speck-free flask and treated dropwise with a speck-free solution of concentrated hydrochloric acid (2.3 ml) in water (62.5 ml). The precipitated product was granulated at pH = 7 and 10°C for 1 hour, collected by filtration, washed with water and dried under vacuum to give the title compound (10.70 g, 90.2%) m.p. 189-190°C. Found: C.55.55; H,6.34; N, 17.69. C22H30N6O4S requires C,55.68; H.6.37; N,17.71%. δ (CD3SOCD3): 0.94(3H,t), 1.32(3H,t), 1.73(2H,h), 2.15(3H,s), 2.35(4H,br s), 2.76(2H,t), 2.88(4H,br s), 4.14(3H,s), 4.18(2H,q), 7.36(1H,d), 7.80(2H,m), 12.16(1H,br s).
Analysis of the product by HPLC and quantitativeTLC indicated that clinical quality material had been obtained directly from the reaction.
/7) The yield of clinical quality material can be increased to 95% by conducting the cyclisation under more concentrated conditions.
EXAMPLES 2-5
Clinical quality material was obtained by variation of the solvent, using procedures similar to that described in Example 1, as summarised in Table 1. As for Example 1, the reactions were carried out at reflux temperature, except in the esses of Examples 2 and 5 where a temperature of 100°C was employed.
AP/P/ 9 7 / 0 1 0 09
ΑΡ. 00717 ζ- ,
-11TABLE 1
| EXAMPLE | SOLVENT | REACTION TIME (HOURS) | % YIELD |
| 2 | t-amyl alcohol | 5 | 78 |
| 3 | ethanol | 9.5 | 83 |
| 4 | tetra hydrofuran | 32 | 81 |
| 5 | 1 -methyicyciohexanol | 4 | 65 |
EXAMPLES 6-9
Clinical quality material was obtained by variation of the solvent and the base, using procedures similar to that described in Example 1, as summarised in Table 2. The reactions were carried out at reflux temperature, except in the case of Example 9 where a temperature of 100°C was employed.
TABLE 2
| EXAMPLE | BASE | SOLVENT | REACTION TIME (HOURS) | % YIELD |
| 6 | sodium ethoxide | t-butanol | 10 | 86 |
| 7 | sodium ethoxide | ethanol | 7 | 82.5 |
| 8 | sodium hydride | tetra hydrofuran | 48 | 84 |
| 9 | cesium carbonate | t-amyl alcohol | 17 | 71 |
AP/P/ 9 7 / 0 1 0 09
AP. Ο Ο 717
-12EXAMPLE 10
Clinical quality material (88%) was obtained by variation of the cation, using a procedure similar to that described in Example 1, when sodium t-butoxide was used as base and the reaction was conducted for 24 hours.
EXAMPLE 11
Clinical quality material (71%) was obtained by variation of the molar ratio of base, using a procedure similar to that described in Example 1, when potassium t10 butoxide (5.0 mol.equiv.) was used and the reaction was conducted at reflux temperature for 18 hours.
EXAMPLE 12
Further variation of the reaction conditions of Example 1, using 1.6 mol.
equiv. of potassium t-butoxide (4.49 g, 0.040 mol) at 60°C for 55 hours, provided the titie compound (87%) of purity >99% by HPLC and TLC analyses.
EXAMPLE 13
Title compound (87%) of purity >99% by HPLC and TLC analyses was 20 obtained, using a procedure similar to that described in Example 1, when 1,4\ dioxan was used as solvent and the reaction was conducted at 100°C for 4 hours.
··’ ;A • :}
EXAMPLE 14
Title compound (85%) of purity >99% by HPLC and TLC analyses was 25 obtained, using a procedure similar to that described in Example 1, when 1,2dimethoxyethane was used as solvent and the reaction was conducted for 30 hours.
AP/P/ 9 7 / 0 1 0 09
AP.00717
-13EXAMPLE 15
Title compound (83%) of purity >99% by HPLC and TLC analyses was obtained, using a procedure similar to that described in Example 1, when 3,75 dimethyloctan-3-ol was used as solvent and the reaction was conducted at 100cC for 16 hours.
EXAMPLE 16
Title compound (74%) of purity >99% by HPLC and TLC analyses was 10 obtained, using a procedure similar to that described in Example 1, when sodium n-decoxide was used as base, 1,4-dioxan was used as solvent and the reaction was conducted at 100°C for 20 hours.
EXAMPLE 17
Title compound (85%) of purity >99% by HPLC and TLC analyses was obtained, using a procedure similar to that described in Example 1, when sodamide was used as base, 1,4-dioxan was used as solvent and the reaction was conducted at 100°C for 18 hours.
EXAMPLE 18 /·> Title compound (91%) of purity >99% by HPLC and TLC analyses was /J obtained, using a procedure similar to that described in Example 1, when sodium cyclohexylamide was used as base, 1,4-dioxan was used as solvent and the reaction was conducted at 100°C for 6.5 hours.
EXAMPLE 19
Title compound (84%) of purity >99% by HPLC and TLC analyses was obtained, using a procedure similar io that described in Example 1, when sodium 4-meihylpiperazide was used as base, 1,4-dioxan was used as solvent and the reaction was conducted at 100°C for 8 hours.
AP/P/ 9 7 / 0 1 0 09
AP.00717
-14EXAMPLES 20-21
Under reaction conditions similar to those described in Example 1, the use of sodium methoxide in methanol for 32 hours furnished a four-component mixture from which the title compound was isolated in a chromatographed yield of 34.5%, whilst the use of potassium t-butoxide in methanol for 40 hours afforded a product mixture which, by TLC and NMR spectroscopic analyses, contained an estimated yield of 69% of the title compound.
EXAMPLE 22 _ Under reaction conditions similar to those described in Example 1, the use of potassium t-butoxide in anhydrous dimethyl sulphoxide at 100°C for 50 hours afforded a crude product (88% wt. yield) which, by TLC and HPLC analyses, contained an estimated yield of 24% of the title compound.
EXAMPLE 23
Under reaction conditions similar to those described in Example 1, the use of magnesium ethoxide in pyridine at reflux temperature for 96 hours gave a crude product (79% wt. yield) which, by TLC and HPLC analyses, contained an estimated yield of 16% of the title compound.
EXAMPLE 24
Under reaction conditions similar to those described in Example 1, the use of barium ethoxide (as a 10% w/v solution in ethanol) in t-amyl alcohol at 100°C for
20 hours provided a crude product (76.5% wt. yield) which, by TLC and HPLC analyses, contained an estimated yield of 75.5% of the title compound.
EXAMPLE 25
Under reaction conditions similar to those described in Example 1, the use of 30 titanium ethoxide in pyridine at 100°C for 90 hours furnished a crude product (82% wt. yield) which, by TLC and HPLC analyses, contained an estimated yield of 32% of the title compound.
AP/P/ 9 7 / 0 1 0 09
AP. Ο Ο 7 1 7
-15EXAMPLE 26
Under reaction conditions similar to those described in Example 1, the use of cupric ethoxide in pyridine at 100°C for 98 hours afforded a crude product (89.5% wt. yield) which, by TLC and HPLC analyses, contained an estimated yield of 18.5% of the title compound.
EXAMPLE 27
Under reaction conditions similar to those described in Example 1, the use of aluminium tri-t-butoxide in pyridine at 100°C for 72 hours gave a crude product which, by TLC and HPLC analyses, contained a maximum (due to aluminium salt contamination) estimated yield of 66% of the title compound.
EXAMPLE 28
Under reaction conditions similar to those described in Example 1, the use of a total of 3.6 mol. equiv. (1.2 mol. equiv. added in three stages) of lithium diisopropylamide (as a 1.5M solution of the mono(tetrahydrofuran) complex in cyclohexane) in anhydrous 1,4-dioxan, initially at 0°C for 15 minutes, then at room temperature for 1 hour and subsequently at 100°C for a total of 140 hours, furnished a crude product (60.5% wt. yield) which, by TLC and HPLC analyses, , contained an estimated yield of 55.5% of the title compound.
<)
EXAMPLE 29
Under reaction conditions similar to those described in Example 1, the use of
2.0 moi.equiv. of 1,8-diazabicyc!o[5.4.0]undec-7-ene in pyridine at 100°C for 44 hours afforded a crude product (6.5% wt. yield) which, by TLC and HPLC analyses, contained an estimated yield of 3.3% of the title compound.
AP/P/ 9 7 / 0 1 0 09
AP. 0 0 7 1 7
-16EXAMPLE 30
Under reaction conditions similar to those described in Example 1, the use of potassium fluoride in t-amyl alcohol at 100°C for 44 hours gave a crude product (85% wt. yield) which, by TLC and HPLC analyses, contained an estimated yield of 3.5% of the title compound.
EXAMPLE 31
85% Potassium hydroxide pellets (3.96 g, 0.06 mol) were added to a stirred 10 suspension of the title compound of Preparation 4 (9.85 g, 0.02 mol) in ethanol _ (30 ml), followed by the’ addition of water (30 ml) which produced a clear solution.
The reaction mixture was heated under reflux for 5 hours and then the bulk of the ethanol removed by evaporation under reduced pressure. The resulting mixture was diluted with water (60 ml), its pH adjusted to 7 using dilute sulphuric acid and the precipitated product granulated for 30 minutes. The solid was collected by filtration, washed with water and dried under vacuum to provide a product (7.96 g), 96.4% of which was shown, by HPLC analysis, to be the title compound.
EXAMPLES 32-34
Under reaction conditions similar to those described in Example 1, the use of :¾ barium oxide in acetonitrile at reflux temperature for 52 hours gave the title compound (89%) of purity >99% by HPLC and TLC analyses.
Repetition using dimethylformamide as solvent at 100°C for 31 hours provided a crude product (75.5% wt. yield) which, by TLC and HPLC analyses, contained an estimated yield of 54% of the title compound.
Further repetition using pyridine as solvent at 100°C for 16 hcurs furnished a crude product which, by TLC and HPLC analyses, contained a maximum (due tc barium salt contamination) estimated yield of 90% of the title compound.
AP/P/ 9 7 / 0 1 0 09
AP. Ο Ο 7 1 7
-17EXAMPLE 35
Under reaction conditions similar to those described in Example 1, the use of cesium carbonate in 4-methylpentan-2-one (methyl isobutyl ketone) at 100°C for
96 hours afforded a crude product (18.5% wt. yield) which, by TLC and HPLC analyses, contained an estimated yield of 13% of the title compound.
EXAMPLE 36
Under reaction conditions similar to those described in Example 1, the use of 10 potassium bicarbonate in t-amyi alcohol at 100°C for 115 hours gave a crude product (82.5% wt. yield) which, by TLC and HPLC analyses, contained an estimated yield of 20% of the title compound.
EXAMPLE 37
The title compound of Preparation 4 (12.32 g, 0.025 moi) was heated at 215220°C for 40 minutes and the resulting melt allowed to cool to room temperature. The tarry crude product was dissolved in dichloromethane (25 ml) and then purified by chromatography on silica gel, using increasingly polar mixtures of methanol in dichloromethane as eluant. Evaporation under vacuum of the appropriate single component fractions provided the pure (by 1H nmr analysis) /J title compound (1.76 g, 14.8%), whilst a batch of less pure title compound (0.87 g, vf- 7.3 %) was obtained from further fractions. Further chromatographic processing of the latter gave an additional quantity (0.48 g) of pure title compound, the total yield being 2.24 g, 18.8%.
EXAMPLES 38-40
A stirred mixture cf the title compound of Preparation 4 (12.32 g, 0.025 mol) and 1,2-dichlorobenzene (61 ml) was heated under reflux for 72 hours. The resulting dark brown reaction mixture was allowed to cool, diluted with dichloromethane (60 ml) and filtered. Evaporation under reduced pressure of the filtrate gave a solvent-containing dark brown oil (17.51 g), 23.2% of the solventAP/P/ 9 7 / 0 1 0 09
AP . 0 0 7 1 7
-18excluded material of which was shown, by TLC and HPLC analyses, to be the title compound.
Repetition using sulpholane as solvent at about 205°C for 5 hours provided a 5 crude product (14% wt. yield) which, by TLC and HPLC analyses, contained an estimated yield of 12% of the title compound.
Further repetition using N-methylpyrroIidin-2-one as solvent at 205-210°C for hours provided a crude product (21.5% wt. yield) which, by TLC and HPLC analyses, contained an estimated yield of 5.5% of the title compound.
: EXAMPLE 41
Under reaction conditions similar to those described in Example 38, except that the reaction was conducted for 24 hours in the presence of 4A molecular sieves, a solvent-containing product was obtained, 6.0% of the solvent-excluded materia! of which was shown, by HPLC analysis, to be the title compound.
EXAMPLE 42
Concentrated sulphuric acid (1.0 mi, 1.84 g, 18.75 mmol) was added to a stirred suspension of the title compound of Preparation 4 (12.32 g, 0.025 mol) in chlorobenzene (61 ml) and then the resulting mixture heated until solvent began to distil out. When the distillate was no longer cloudy (after collection of ca. 20 ml), the reaction mixture was allowed to cool to room temperature and a further quantity (20 ml) of chlorobenzene added before it was heated under reflux for 20 hours. The cool reaction mixture was treated with dichloromethane (100 mi) to form a solution, followed by water (100 ml). The pH of the resulting mixture was adjusted to 7 using 5M aqueous sodium hydroxide solution, then the organic phase separated, combined with a dichloromethane extract (50 ml) of the aqueous phase and evaporated under reduced pressure to furnish a solid (9.51 g), 5.5% of which was shown, by HPLC snsiysis, to be the title compound.
AP/P/ 9 7 / 0 1 0 09
AP. Ο ο 7 1 7
-19EXAMPLE 43
Concentrated sulphuric acid (1.0 ml, 1.84g, 18.75 mmol) was added to a stirred solution of the title compound of Preparation 4 (6.16g, 12.5 mmol) in glacial acetic acid (31 ml) and the resulting mixture heated at 100°C for 115 hours. The solvent was removed by evaporation under reduced pressure, the residue “azeotroped” with toluene (2 x 50 ml) and the resulting oil (10.5 g) shaken with water (60 ml) to give a crystalline solid which was collected, washed with water (10 ml) and dried. This crop (2.03 g) was combined with a second crop (3.48g) obtained by neutralisation of the filtrate with 20% aqueous sodium hydroxide solution, followed by collection, washing and drying as before, to provide the crude product (5.51 g) which, by TLC and HPLC analyses, contained an estimated yield of 38% of the title compound.
EXAMPLE 44
A stirred mixture of the title compound of Preparation 4 (6.16 g, 12.5 mmol) and glacial acetic acid (31 mi) was heated at 100°C for 7 hours and the resulting solution allowed to cool. TLC analysis of the reaction mixture showed that none of the title compound was present at this stage.
85% Aqueous phosphoric acid solution (0.5 ml) was added and the resulting mixture heated at 100°C, intermittently, for a total of 300 hours, then evaporated
A ) under reduced pressure. The residue was “azeotroped” with toluene and dissolved in water (50 ml), then the pH of the stirred aqueous solution adjusted to 7 with 20% aqueous sodium hydroxide solution. Stirring was continued for 2 hours, then the precipitate collected, washed with water (20 ml) and dried under vacuum at 50°C, to give the crude product (5.21 g) which, by TLC and HPLC analyses, contained an estimated yield of 9.1% of the title compound.
EXAMPLE 45
A stirred mixture of D-tciuenesulphonic acid monohydrate (5.71 g, 0.030 mol) and chlorobenzene (100 ml) was heated under reflux until all the water had been
AP/P/ 9 7 / 0 1 0 09
AP. Ο Ο 7 1 7
-20removed, using a Dean-Stark trap, and then allowed to cool to room temperature. The title compound of Preparation 4 (24.64 g, 0.050 mol) was added and the reaction mixture stirred under reflux for 24 hours, then allowed to cool. To the resulting mixture was added dichioromethane (200 ml) and water (200 ml), the pH was adjusted to 7 using 2M aqueous sodium hydroxide solution, and the organic phase separated and combined with a dichioromethane extract (100 mi) of the aqueous phase. The combined organic phases were washed with water (100 ml) and evaporated under reduced pressure to afford an off-white solid (24.86 g),
7.3% of which was shown, by TLC and HPLC analyses, to be the title compound.
EXAMPLE 46
Titanium tetrachloride (3.3 mi, 5.69 g, 0.030 mol) was added to a stirred suspension of the title compound of Preparation 4 (12.32 g, 0.025 mol) in anhydrous 1,4-dioxan (61 ml), during which vigorous evolution of a gas was noted. The stirred reaction mixture was heated at about 70°C for 7.5 hours, allowed to cool to room temperature and then treated with water (200 ml) and concentrated hydrochloric acid (50 ml) to give a clear solution. The solution was washed with dichioromethane and its pH adjusted to 12 using 40% aqueous sodium hydroxide solution; it was then stirred for 10 minutes and its pH further adjusted to 7 using I 5M hydrochloric acid. The precipitate was removed by filtration and washed with ,¾) dichioromethane (2 x 200 mi), then the combined dichioromethane washings were used to extract the aqueous filtrate and evaporated under reduced pressure to give a solid (11.36 g), 33.7% of which was shown, by TLC and HPLC analyses, to be the title compound.
EXAMPLES 47-52
Under reaction conditions similar to those described in Example 46, the variations of which are summarised in Table 3, alternative Lewis acids provided the corrected yields of title compound shown.
AP/P/ 9 7 / 0 1 0 09
-21TABLE 3
| EXAMPLE | LEWIS ACID | SOLVENT | REACTION TIME (HOURS) | % YIELD |
| 47 | bf3’ | tetrahydrofuran | 72 | 7.0 |
| 48 | aici3 | 1,4-dioxan | 30 | 7.8 |
| 49 | FeCl3 | tetrahydrcfuran | 24 | 6.3 |
| 50 | ZnCI2 | tetrahydrofuran | 72 | 2.8 |
| 51 | SiCI4 | 1,4-dioxan | 44 | 20.5 |
| 52 | SnCI4 | 1,4-dioxan | 48 | 30.8 |
* as the diethyl etherate
AP/P/ 9 7 / 0 1 0 09
AP. ύ Ο 7 1 7
-22PREPARATION 1
5-Chlorosulphonyl-2-ethoxybenzoic acid
Molten 2-ethoxybenzoic acid (25.0 g, 0.150 mol) was added to a stirred, ice5 cooled mixture of thionyl chloride (11 ml, 0.151 mol) and chlorosulphonic acid (41.3 ml, 0.621 mol), whilst maintaining the temperature of the reaction mixture below 25°C. The resulting mixture was stirred at room temperature for 18 hours and then poured into a stirred mixture of ice (270 g) and water (60 ml) to give an off-white precipitate. Stirring was continued for 1 hour, then the product was collected by filtration, washed with water and dried under vacuum to provide the _ title compound (36.08 g). A reference sample, m.p. 115-116°C, was obtained by crystallisation from hexaneitoluene. Found: C,41.02; H,3.27. C9HsCIO5S requires C,40.84; H,3.43%. δ (CDCI3): 1.64(3H,t), 4.45(2H,q), 7.26(1H,d), 8.20(1H,dd), 8.80(1H,d).
PREPARATION 2
2-Ethoxy-5-(4-methylpioerazin-1-ylsulphonyl)benzoic acid (a): one-step procedure
1-Methylpiperazine (33.6 ml, 0.303 mol) was added to a stirred suspension 20 of the title compound of Preparation 1 (34.4 g, 0.130 mol) in water (124 ml) at about 10°C, whilst maintaining the temperature of the reaction mixture below 20°C. The resulting solution was cooled to about 10°C and, after 5 minutes, crystallisation of a solid commenced. After a further 2 hours, the solid was collected by filtration, washed with ice-water and dried under vacuum to furnish the crude product (36.7 g). A sample (15.0 g) was purified by stirring it in refluxing acetone for 1 hour; the resulting suspension was allowed to cool to room temperature and the crystalline solid collected by filtration and dried under vacuum to afford the title compound (11.7 g), m.p. 198-199°C, whose 1H nmr spectrum is identical with that obtained for the product of procedure (b) beiow.
AP/P/ 9 7 / 0 1 0 09
ΑΚ Ο Ο 7 1 7
-23(b): two-step procedure
A solution of the title compound of Preparation 1 (50.0 g, 0.189 mol) in acetone (150 ml) was added dropwise to a stirred mixture of 1-methylpiperazine (20.81 g, 0.208 moi) and triethylamine (28.9 ml, 0.207 mol), whilst maintaining the temperature of the reaction mixture below 20°C. A white crystalline solid formed during the addition and stirring was continued for a further 1.5 hours. Filtration, followed by washing with acetone and drying under vacuum of the product, provided the hydrochioride-triethylamine double salt of the title compound (78.97
g), m.p. 166-169°C. Found: C,51.33; H,8.14; N,9.06; Cl,8.02. C14H20N2O5S;
CeH15N; HCI requires 0,51.55; H.7.79; N,9.02; Cl, 7.61%. δ (CD3SOCD3):
1.17(9H,t), 1.32(3H,t), 2.15(3H,s), 2.47(6H,br s), 2.86(2H, br s), 3.02(6H,q), 4.18(2H,q), 7.32(1H,d), 7.78(1H,dd), 7.85(1H,d).
The double salt (30.0 g) was stirred in water (120 ml) to produce an almost clear solution, from which crystallisation of a solid rapidly occurred. After 2 hours, the solid was collected by filtration, washed with water and dried under vacuum to give the title compound (14.61 g) as a white solid. A reference sample, m.p.
201 °C, was obtained by recrystallisation from aqueous ethanol. Found; C.51.09;
H.6.16; N.8.43. C14H20N2O5S requires C,51.21; H,6.14; N,8.53%. δ (CD3SOCD3):
1.31 (3H,t), 2.12(3H,s), 2.34(4H,br s), 2.84(4H, br s), 4.20(2H,q), 7.32(1H,d),
7.80(1 H.dd), 7.86(1 H,d).
PREPARATION 3
4-Amino-1-methyl-3-n-propylpyrazole-5-carboxamide
A stirred suspension of 1-methyl-4-nitro-3-n-propyipyrazole-5-carboxamide (EP-A-0463756; 237.7 g, 1.12 mol) and 5% palladium on charcoal (47.5 g) in ethyl acetate (2.02 I) was hydrogenated at 344.7 kPa (50 psi) and 50°C for 4 hours, when the uptake of hydrogen was complete. The cool reaction mixture was filtered, then the filter pad washed with ethyl aceiate, ihe combined filtrate and washings thus furnishing an ethyl acetate solution of the title compound (EP-A0463756) which was of sufficient purity to use directly in the next stage of the reaction sequence (see Preparation 4).
AP/P/ 9 7 / 0 1 0 0 9
AP.00717
-24PREPARATION 4
4-[2-Ethoxy-5-(4-methyipiperazin-1-vlsulphonyl)benzamido1-1-methyl-3-npropylpyrazole-5-ca rboxamide
Ν,Ν’-Carbc .nyldiimidazole (210.8 g, 1.30 mol) was washed into a stirred suspension of the title compound of Preparation 2 (408.6 g, 1.24 mol) in ethyl acetate (1.50 I) using ethyl acetate (1.36 I) and the resulting mixture heated at 55°C fcr 0.5 hour and then under reflux for a further 2 hours before being allowed to cool to room temperature. An ethyl acetate solution of the title compound of Preparation 3 (2.185 Kg of solution containing 204 g, 1.12 mol of amine) was added and the reaction mixture stirred at room temperature for 72 hours to afford a crystalline solid which was collected by filtration and dried under vacuum. The title compound (425 g), m.p. 204-206°C, thus obtained was combined with a further crop (70 g) which was recovered by concentration of the mother liquor. A reference sample, m.p. 206-208°C, was obtained by recrystallisation from aqueous methanol. Found: C.53.65; H.6.54; N,17.07. Ο22ΗΞ2Ν6Ο58 requires C,53.64; H.6.55; N,17.06%. δ (CDCI3): 0.96(3H,t), 1.58(3H,t), 1.66(2H,m), 2.27(3H,s), 2.45(4H,m), 2.52(2H,t), 3.05(4H,br s), 4.05(3H,s), 4.40(2H,q),
5.61 (1H, brs), 7.61(1H,d), 7.65(1H, brs), 7.90(1H,dd), 8.62(1H,d), 9.25(1H,brs).
PREPARATION 5
Methyl 2-ethoxvbenzoate
Concentrated sulphuric acid (0.5 mi) was added to a solution of 2ethoxybenzoic acid (50 g, 0.301 mol) in methanol (500 ml) and the resulting mixture heated under reflux for 70 hours, then evaporated under reduced pressure to give an oil which was dissolved in dichloromethane (300 ml). This solution was washed successively with water (150 ml), aqueous sodium bicarbonate solution (150 ml) and water (150 ml), then evaporated under reduced pressure to give the title compound (49.7 a) as an oil. δ (CDCk): 1.44 (3H,t), 3.90 (3H,s), 4.12 (2H,c), 6.95 (2H,m), 7.44 (1 H,t), 7.78 (1 H,d).
AP/P/ 9 7 / 0 1 0 0 9
AP.00717
-25PREPARATION 6
Methvl 5-chlorosulohonyl-2-ethoxybenzoate
The title compound cf Preparation 5 (36.04 g, 0.20 mol) was added dropwise over 10 minutes to stirred, ice-cooled chlorosulphonic acid (59.8 ml, 0.90 mol), whilst maintaining the temperature of the reaction mixture below 22CC. The reaction mixture was stirred at room temperature for 18 hours, then thionyl chloride (14.6 ml, 0.20 mol) added and the resulting solution stirred at room temperature for 6 hours, then poured into a stirred mixture of ice (530 g) and water (120 ml). The quenched mixture was extracted with dichioromethane (2 x 200 ml) and the combined extracts evaporated under reduced pressure to give the crude title compound (44.87 g) as a white solid. A reference sample, m.p. 99-100°C, was obtained by crystallisation from toluene, δ (CDCI3): 1.52 (3H,t), 3.93 (3H,s), 4.25 (2H,q), 4.25 (2H,q), 7.12 (1 H,d), 8.12 (1 H,dd), 8.46 (1H,d).
PREPARATION 7
Methyl 2-ethoxy-5-(4-methylpiperazin-1-ylsulphonyl)benzoate
A solution of the crude title compound of Preparation 6 (27.87 g) in acetone (140 ml) was added dropwise over 10 minutes to a stirred, ice-cooled solution of
1-methylpiperazine (11.02 g, 0.11 mol) and triethylamine (15.3 ml, 0.11 mol) in acetone (140 ml), whilst maintaining the temperature of the reaction mixture below
ΑΑϊ 20°C. A white precipitate formed during the addition and stirring was continued for a further 4 hours. The resulting mixture was filtered, the filtrate evaporated under reduced pressure and the residue azeotroped with toluene to provide a pale brown gum (41.9 g). This crude product was granulated by stirring with water (100 ml) for 2 hours and the resulting material collected by filtration, washed with water (2 x 50 ml) and dried under vacuum ai 50°C to furnish the title compound, m.p. 110-111°C. δ (CDCI3): 1.48 (3H,t), 2.27 (3H,s), 2.47 (4H,t), 3.03 (4H,t), 3.90 (3H,s), 4.18 (2H,q), 7.04 (1H,d), 7.81 (1 H,dd), 8.15 (1H,d).
AP/P/ 9 7 / 0 1 0 09
AP. Ο Ο 7 1 7
-26T'ne compound obtained as abo'. e was shown to be identical with that produced by conventional methyl esterification of the title compound of Preparation 2.
Furthermore, conventional base hydrolysis of the compound obtained as above afforded a product identical with that of Preparation 2.
Claims (6)
1. A process for the preparation of a compound of formula (I):
/ \
SO-N NCH, \_/ which comprises cyclisation of a compound of formula (II):
wherein the cyclisation is carried out in the presence of a base, preferably in a solvent, optionally in the presence of hydrogen peroxide or a peroxide salt, and is followed, where necessary, by neutralisation of the reaction mixture.
25 3
AP. ο 0 717
-28Α process according to ciaim I wherein the base is selected from the group consisting of a metal salt of a 0-,-0-,
2 aikanof, a C3-C12 cycloalkanol, a (C3-Cs cycloalkyOC^Ce alkanol, ammonia, a C-,-C12 alkylamine, a di(Ci-C12 a!kyl)amine, a C3-C8 cycioalkylamine, a N-(C3-C8 cycloaikyO-N/C^C^ a!kyf)amine, a cfi(C3-C8 cycioalkylamine, a (C3-C8 cycloalkylJC^Cg alkylamine, a N-(C3-C8 cycloalkyOCpCg alkyl-N-(C-,-C12 a!kyl)amine, a N-(C3C8 cycloalkyOCrCg alkyl-N-(C3-C8 cycioalkylamine, a di[(C3-C8 cycloalkyQCr C6 alkyl]amine and a heterocyclic amine selected from the group consisting of imidazole, triazole, pyrrolidine, piperidine, heptamethyleneimine, morpholine, thiomorpholine and a 1-(C-,-C4 alkyf)piperazine; a meta! hydride, fluoride, hydroxide, oxide, carbonate and bicarbonate; wherein the metal is selected from the group consisting of lithium, sodium, potassium, rubidium, cesium, beryllium, magnesium, calcium, strontium, barium, aluminium, indium, thallium, titanium, zirconium, cobalt, copper, silver, zinc, cadmium, mercury and cerium; and a C7-C12 bicyclic amidine;
and the solvent is selected from the group consisting of a CrC12 alkanol, a C3-C12 cycloalkanol, a (C3-C8 cycloalkyOC^Cg alkanol, a C3-C9 alkanone, a C4-C10 cycioaikanone, a C5-C12 aikyf ether, 1,2-dimethoxyethane, 1,2diethoxyethane/diglyme, tetrahydrofuran, 1,4-dioxan, benzene, toluene, xylene, chlorobenzene, dichlorobenzene, acetonitrile, dimethyl sulphoxide, sulpholane, dimethylformamide, dimethyiacetamide, N-methyipyrrolidin-2one, pyrrolidin-2-one, pyridine and water, and mixtures thereof.
A process according to claim 2 wherein the base is selected from the group consisting of an alkali or alkaline earth metal salt of a CrC12 alkanol, a C3C12 cycloalkanol and a (C3-Cs cycloa(kyl)C1-C5 alkanol; an alkali metal salt of ammonia, a N-(secondary or tertiary C3-C6 alkyl)-N-(primary, secondary or tertiary C3-C6 alkyl)amine, a C3-C8 cycioalkylamine, a N-(C3-C3 cyc!oalkyl)-NAP. 0 0 7 1 7
-29(primary, secondary or tertiary C3-Cs alkyl)amine, a di(C3-C8 cycloaikyl)amine and 1-methylpiperazine; an alkali or alkaline earth metal hydride, hydroxide, oxide, carbonate and bicarbonate; 1,5-diazabicyclo[4.
3.0]non-5-ene and 1,8diazabicyclo[5.
4.0]undec-7-ene;
and the solvent is selected from the group consisting of ethanol, 2-propanol, a secondary or tertiary C4-C12 alkanol, a C3-C12 cycloalkanol, a tertiary C4-C12 cycloalkanol, a secondary or tertiary (C3-C7 cycioalkyi)C2-C6 aikanoi, a C3-C9 alkanone, 1,2-dimethoxyethane, 1,2-diethoxyethane, digiyme, tetrahydrofuran, 1,4-dioxan, toluene, xylene, chlorobenzene, 1,2dichlorobenzene, acetonitrile, dimethyl sulphoxide, suipholane, dimethylformamide, N-methyipyrroiidin-2-one, pyridine and water, and mixtures thereof.
A process according to any one of claims I to 3 wherein the reaction is carried out at from 50 to 170°C for from 3 to 170 hours.
A process according to claim 4-wherein the quantity of base employed is from 1.0 to 5.0 molecular equivalents.
A process according to claim 5 wherein the base is selected from the group consisting of the lithium, sodium and potassium salts of a aikanoi, a
C4-C12 cycloalkanol, ammonia, cyclohexylamine and 1-methylpiperazine; the hydride salts of lithium, sodium and potassium; cesium carbonate; and barium oxide; the solvent is selected from the group consisting of ethanol, a tertiary C4-C10 alcohol, a tertiary C5-C3 cycloalkanol, tetrahydrofuran, 1,4dioxan and acetonitrile, the reaction is carried out at from 60 to 105°C and the quantity of base employed is from 1.1 to 2.0 molecular equivalents.
A process according to claim d wherein the base is selected from the group consisting of the CrC12 alkoxide and hydride salts of lithium, sodium and
-30potassium, sodamide, sodium cyciohexylamide and cesium carbonate; the solvent is selected from the group consisting of ethanol, t-butanoi, t-amyl alcohol, 1-methylcyciohexanol, tetrahydrofuran and 1,4-dioxan; and the
5 reaction is conducted for from 3 to 60 hours.
S . A process according to claim 7 wherein the base is selected from the group consisting of sodium ethoxide, sodium t-butoxide, potassium t-butoxide and sodium hydride; and the solvent is selected from the group consisting of
10 ethanol, t-buianol, t-amyl alcohol and tetrahydrofuran.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9612514.1A GB9612514D0 (en) | 1996-06-14 | 1996-06-14 | Novel process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP9701009A0 AP9701009A0 (en) | 1997-07-31 |
| AP717A true AP717A (en) | 1999-01-04 |
Family
ID=10795332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/1997/001009A AP717A (en) | 1996-06-14 | 1997-06-02 | Process for preparing sildenafil. |
Country Status (47)
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060222647A1 (en) * | 1993-05-27 | 2006-10-05 | Beavo Joseph A | Methods and compositions for modulating the activity of PDE5 |
| CA2288910C (en) | 1997-04-25 | 2003-06-24 | Pfizer Inc. | Pyrazolopyrimidinones for sexual dysfunction |
| EP0992240A4 (en) * | 1997-05-29 | 2003-04-16 | Mochida Pharm Co Ltd | Therapeutic agent for erection failure |
| US6399618B1 (en) | 1997-07-09 | 2002-06-04 | Cardiome Pharma Corp | Compositions and methods for modulating sexual activity |
| GB9722520D0 (en) | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
| NZ504436A (en) * | 1997-11-12 | 2001-08-31 | Bayer Ag | 2-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
| DE69910368T2 (en) | 1998-04-20 | 2004-03-25 | Pfizer Inc. | PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUALFUNCTIONAL DISORDERS |
| CA2235642C (en) | 1998-05-15 | 2007-11-13 | Torcan Chemical Ltd. | Processes for preparing sildenafil |
| ATE264861T1 (en) * | 1998-09-04 | 2004-05-15 | Ortho Mcneil Pharm Inc | 5-HETEROCYCLYL-PYRAZOLO(4,3-D)PYRIMIDINE-7-ONE FOR THE TREATMENT OF MALE ERECTILE DYSFUNCTION |
| GB9822238D0 (en) * | 1998-10-12 | 1998-12-09 | Pfizer Ltd | Process for preparation of pyrazolo[4,3-D]pyrimidin-7-ones and intermediates thereof |
| GB9823102D0 (en) | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
| GB9823101D0 (en) | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
| GB9823103D0 (en) * | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
| KR100353014B1 (en) * | 1998-11-11 | 2002-09-18 | 동아제약 주식회사 | Pyrazolopyrimidinone derivatives for the treatment of impotence |
| US6087362A (en) * | 1999-03-16 | 2000-07-11 | Pentech Pharmaceuticals, Inc. | Apomorphine and sildenafil composition |
| CN1094492C (en) * | 1999-06-21 | 2002-11-20 | 杭州神鹰医药化工有限公司 | Process for preparing 'Xidinafei' medicine |
| AU5204800A (en) * | 1999-06-21 | 2001-01-09 | Biochemical Pharmaceutical Factory of Zhuhai Sez, The | Process for preparing sildenafil, and troche which comprises sildenafil and apomorphine |
| CN1077108C (en) * | 1999-07-13 | 2002-01-02 | 成都地奥制药集团有限公司 | Precursor compound for preparing medicine 'Xiduofeng' |
| AU1888800A (en) * | 1999-09-13 | 2001-04-17 | Cipla Limited | A novel process for the synthesis of sildenafil citrate |
| US6075028A (en) * | 1999-09-23 | 2000-06-13 | Graham; Richard | Method of treating Tourette's syndrome and related CNS disorders |
| TWI265925B (en) * | 1999-10-11 | 2006-11-11 | Pfizer | Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them |
| KR20020038941A (en) | 1999-10-11 | 2002-05-24 | 디. 제이. 우드, 스피겔 알렌 제이 | 5-(2-Substituted-5-Heterocyclylsulphonylpyrid-3-yl)-Dihydropyrazolo[4,3-D]Pyrimidin-7-Ones as Phosphodiesterase Inhibitors |
| EP1296983B1 (en) * | 2000-06-22 | 2004-11-17 | Pfizer Limited | Novel process for the preparation of pyrazolopyrimidinones |
| US6730786B2 (en) * | 2000-06-22 | 2004-05-04 | Pfizer Inc | Process for the preparation of pyrazolopyrimidinones |
| GB0015462D0 (en) * | 2000-06-22 | 2000-08-16 | Pfizer Ltd | Novel process for the preparation of pyrazolopyrimidinones |
| US6667398B2 (en) | 2000-06-22 | 2003-12-23 | Pfizer Inc | Process for the preparation of pyrazolopyrimidinones |
| EP1176147A1 (en) * | 2000-07-28 | 2002-01-30 | Pfizer Limited | Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof |
| EP1176142A1 (en) * | 2000-07-28 | 2002-01-30 | Pfizer Inc. | Process for the preparation of pyrazoles |
| US6407259B1 (en) | 2000-07-28 | 2002-06-18 | Pfizer Inc. | Process for the preparation of pyrazoles |
| US6821978B2 (en) * | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
| CN1127506C (en) * | 2001-06-29 | 2003-11-12 | 刘宝顺 | Compound for treating impotence |
| ATE395349T1 (en) * | 2001-08-28 | 2008-05-15 | Schering Corp | POLYCYCLIC GUANINE PHOSPHODIESTERASE INHIBITORS |
| SI1509525T1 (en) | 2002-05-31 | 2006-12-31 | Schering Corp | Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof |
| DE10232113A1 (en) | 2002-07-16 | 2004-01-29 | Bayer Ag | Medicinal products containing vardenafil hydrochloride trihydrate |
| CN100374441C (en) | 2003-06-06 | 2008-03-12 | 天津倍方科技发展有限公司 | Dihydropyrrole[2,3-d]pyrimidin-4-one derivatives, preparation method and pharmaceutical use thereof |
| CN100360531C (en) * | 2003-12-18 | 2008-01-09 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | Pyrazolopyrimidine compounds for prevention and cure of impotence and frigidity |
| PL1633364T3 (en) | 2004-01-05 | 2008-07-31 | Teva Pharma | Processes for the production of sildenafil base and citrate salt |
| EP1779852A3 (en) * | 2004-01-05 | 2007-05-09 | Teva Pharmaceutical Industries Ltd. | Processes for the production of sildenafil base and citrate salt |
| DE102005009240A1 (en) | 2005-03-01 | 2006-09-07 | Bayer Healthcare Ag | Dosage forms with improved pharmacokinetic properties |
| WO2008074194A1 (en) * | 2006-12-21 | 2008-06-26 | Topharman Shanghai Co., Ltd. | A process for the preparation of sildenafil and the intermediates thereof |
| ES2310144B1 (en) | 2007-06-15 | 2010-01-12 | Galenicum Health, S.L. | INTERMEDIATES FOR THE PREPARATION OF A TYPE 5 PHOSPHODIESTERASE INHIBITOR. |
| EP2374460A4 (en) | 2008-12-12 | 2013-08-21 | Rhein Siegfried Sa De Cv | Pulsed-release sildenafil composition and method for preparing said composition |
| MX2010006227A (en) | 2010-06-07 | 2011-12-14 | World Trade Imp Exp Wtie Ag | Novel 1,4-diazepam pde-5 inhibitor derivatives. |
| CN102993205B (en) * | 2012-12-27 | 2015-04-15 | 华润赛科药业有限责任公司 | High-yield purification method for preparation of high-purity sildenafil freebases |
| CN103044330B (en) * | 2013-01-14 | 2018-11-13 | 常州亚邦制药有限公司 | The new green synthesizing process of silaenafil intermediate 4- amino -1- methyl -3- n-propyl pyrazoles -5- formamides |
| CN105085526B (en) * | 2014-05-15 | 2017-08-01 | 重庆圣华曦药业股份有限公司 | A kind of improved silaenafil preparation method |
| CN105753870B (en) * | 2016-04-01 | 2018-05-22 | 重庆康刻尔制药有限公司 | A kind of silaenafil impurity F and its preparation method and application |
| WO2017168174A1 (en) | 2016-04-02 | 2017-10-05 | N4 Pharma Uk Limited | New pharmaceutical forms of sildenafil |
| CN105837578A (en) * | 2016-04-05 | 2016-08-10 | 重庆康刻尔制药有限公司 | Synthesis method of sildenafil impurity D |
| EP3522920A2 (en) | 2016-10-10 | 2019-08-14 | Transgene SA | Immunotherapeutic product and mdsc modulator combination therapy |
| CN113493459B (en) * | 2020-04-07 | 2022-12-13 | 广州白云山医药集团股份有限公司白云山制药总厂 | PDE5 inhibitor compound, preparation method and application thereof |
| CN112961160A (en) * | 2021-03-05 | 2021-06-15 | 遂成药业股份有限公司 | Improved synthesis process of sildenafil |
| CN113754612B (en) * | 2021-10-26 | 2023-09-26 | 山东安舜制药有限公司 | A kind of preparation method of sildenafil intermediate |
| CN119874665B (en) * | 2025-01-16 | 2025-10-17 | 常州大学 | A method for preparing 2-phenylbenzo-1,3-thioxadiene-4-one by HI catalysis |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0463756A1 (en) * | 1990-06-20 | 1992-01-02 | Pfizer Limited | Pyrazolopyrimidinone antianginal agents |
| EP0526004A1 (en) * | 1991-07-09 | 1993-02-03 | Pfizer Limited | Pyrazolopyrimidinone antianginal agents |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4282361A (en) | 1978-03-16 | 1981-08-04 | Massachusetts Institute Of Technology | Synthesis for 7-alkylamino-3-methylpyrazolo [4,3-d]pyrimidines |
| US4871843A (en) * | 1983-10-18 | 1989-10-03 | Dropic-Societe Civile De Gestion De Droits De Propriete Industrielle | Cyclic benzenesulfonamides, process for their preparation and their use as active substance of pharmaceutical compositions |
| GB9311920D0 (en) * | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
| CA2288910C (en) * | 1997-04-25 | 2003-06-24 | Pfizer Inc. | Pyrazolopyrimidinones for sexual dysfunction |
| US6087368A (en) * | 1998-06-08 | 2000-07-11 | Bristol-Myers Squibb Company | Quinazolinone inhibitors of cGMP phosphodiesterase |
-
1996
- 1996-06-14 GB GBGB9612514.1A patent/GB9612514D0/en active Pending
-
1997
- 1997-05-14 HN HN1997000072A patent/HN1997000072A/en unknown
- 1997-05-30 NO NO972481A patent/NO304551B1/en not_active IP Right Cessation
- 1997-06-02 AP APAP/P/1997/001009A patent/AP717A/en active
- 1997-06-04 EP EP98123740A patent/EP0916675B1/en not_active Expired - Lifetime
- 1997-06-04 SI SI9730005T patent/SI0812845T1/en not_active IP Right Cessation
- 1997-06-04 DE DE69700321T patent/DE69700321T2/en not_active Expired - Lifetime
- 1997-06-04 DK DK97303832T patent/DK0812845T3/en active
- 1997-06-04 EP EP97303832A patent/EP0812845B1/en not_active Expired - Lifetime
- 1997-06-04 SI SI9730577T patent/SI0916675T1/en unknown
- 1997-06-04 AT AT97303832T patent/ATE182150T1/en active
- 1997-06-04 AT AT98123740T patent/ATE246194T1/en active
- 1997-06-04 PT PT98123740T patent/PT916675E/en unknown
- 1997-06-04 ES ES97303832T patent/ES2134051T3/en not_active Expired - Lifetime
- 1997-06-04 ES ES98123740T patent/ES2201397T3/en not_active Expired - Lifetime
- 1997-06-04 DE DE69723846T patent/DE69723846T2/en not_active Expired - Lifetime
- 1997-06-04 DK DK98123740T patent/DK0916675T3/en active
- 1997-06-05 IL IL12541197A patent/IL125411A/en not_active IP Right Cessation
- 1997-06-05 BG BG101569A patent/BG62554B1/en unknown
- 1997-06-05 IL IL12100097A patent/IL121000A/en not_active IP Right Cessation
- 1997-06-05 TR TR97/00470A patent/TR199700470A2/en unknown
- 1997-06-06 US US08/869,532 patent/US5955611A/en not_active Expired - Lifetime
- 1997-06-10 SK SK1784-2001A patent/SK283895B6/en not_active IP Right Cessation
- 1997-06-10 SA SA97180124A patent/SA97180124B1/en unknown
- 1997-06-10 IN IN1548DE1997 patent/IN187350B/en unknown
- 1997-06-10 SK SK743-97A patent/SK283893B6/en not_active IP Right Cessation
- 1997-06-10 SK SK1787-2001A patent/SK283897B6/en not_active IP Right Cessation
- 1997-06-10 IS IS4503A patent/IS1922B/en unknown
- 1997-06-10 SK SK1786-2001A patent/SK283896B6/en not_active IP Right Cessation
- 1997-06-10 SK SK1783-2001A patent/SK283894B6/en not_active IP Right Cessation
- 1997-06-11 DZ DZ970097A patent/DZ2247A1/en active
- 1997-06-11 EA EA199700061A patent/EA000102B1/en not_active IP Right Cessation
- 1997-06-11 PE PE1997000483A patent/PE1299A1/en not_active IP Right Cessation
- 1997-06-11 MA MA24655A patent/MA24205A1/en unknown
- 1997-06-11 TN TNTNSN97102A patent/TNSN97102A1/en unknown
- 1997-06-11 PE PE2001000983A patent/PE20011303A1/en not_active IP Right Cessation
- 1997-06-12 UA UA97062802A patent/UA27085C2/en unknown
- 1997-06-12 SG SG1997002037A patent/SG50024A1/en unknown
- 1997-06-12 EG EG54097A patent/EG24123A/en active
- 1997-06-12 CZ CZ19971811A patent/CZ290942B6/en not_active IP Right Cessation
- 1997-06-12 AR ARP970102564A patent/AR003401A1/en unknown
- 1997-06-12 CA CA002207694A patent/CA2207694C/en not_active Expired - Lifetime
- 1997-06-12 ID IDP972004A patent/ID18745A/en unknown
- 1997-06-13 OA OA70024A patent/OA10426A/en unknown
- 1997-06-13 KR KR1019970024457A patent/KR100207352B1/en not_active Expired - Fee Related
- 1997-06-13 MX MX9704433A patent/MX9704433A/en unknown
- 1997-06-13 RS YUP-254/97A patent/RS49653B/en unknown
- 1997-06-13 NZ NZ328084A patent/NZ328084A/en not_active IP Right Cessation
- 1997-06-13 AU AU24878/97A patent/AU697684B2/en not_active Ceased
- 1997-06-13 CO CO97032741A patent/CO4780028A1/en unknown
- 1997-06-13 JP JP9156422A patent/JP2866841B2/en not_active Expired - Lifetime
- 1997-06-13 CN CN97113261A patent/CN1106399C/en not_active Expired - Lifetime
- 1997-06-13 UY UY24585A patent/UY24585A1/en not_active IP Right Cessation
- 1997-06-13 HR HR970326A patent/HRP970326B1/en not_active IP Right Cessation
- 1997-06-13 PL PL97320555A patent/PL189333B1/en not_active IP Right Cessation
- 1997-06-13 HU HU9701048A patent/HU224497B1/en not_active IP Right Cessation
- 1997-06-13 ZA ZA9705259A patent/ZA975259B/en unknown
- 1997-06-13 RS YUP-2006/0484A patent/RS49924B/en unknown
- 1997-06-16 BR BR9703580A patent/BR9703580A/en not_active IP Right Cessation
- 1997-07-09 UY UY24612A patent/UY24612A1/en not_active IP Right Cessation
-
1998
- 1998-07-20 IL IL12541198A patent/IL125411A0/en unknown
- 1998-09-25 JP JP10271067A patent/JP3058863B2/en not_active Expired - Lifetime
- 1998-10-30 NO NO985064A patent/NO306115B1/en not_active IP Right Cessation
-
1999
- 1999-07-23 US US09/360,128 patent/US6066735A/en not_active Expired - Lifetime
- 1999-08-26 GR GR990402170T patent/GR3031087T3/en unknown
-
2000
- 2000-07-05 CN CNB001200542A patent/CN1149206C/en not_active Expired - Lifetime
-
2001
- 2001-04-24 IN IN519DE2001 patent/IN187319B/en unknown
- 2001-04-24 IN IN518DE2001 patent/IN187318B/en unknown
- 2001-04-24 IN IN520DE2001 patent/IN187320B/en unknown
- 2001-04-24 IN IN517DE2001 patent/IN187317B/en unknown
-
2002
- 2002-11-25 IS IS6634A patent/IS1923B/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0463756A1 (en) * | 1990-06-20 | 1992-01-02 | Pfizer Limited | Pyrazolopyrimidinone antianginal agents |
| EP0526004A1 (en) * | 1991-07-09 | 1993-02-03 | Pfizer Limited | Pyrazolopyrimidinone antianginal agents |
Non-Patent Citations (1)
| Title |
|---|
| J. Med. Chem. Vol. 30, No. 1, 1987 pp. 91-96 XP 002040681, HAMILTON et al.: "Synthesis and Structure-Activity Relationships of Pyrazolo[4,3-d pyrimidin-7-ones as Adenosine Receptor Antagonists" Conversion of "6" to "5". * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP717A (en) | Process for preparing sildenafil. | |
| EP0274379B1 (en) | Process for preparing pyridine-2,3-dicarboxylic acid compounds | |
| US6207829B1 (en) | Process for preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof | |
| EP1092720B1 (en) | Process for the preparation of pyrazolo [4,3-d] pyrimidin-7-ones-3-pyridylsulphonyl compounds and intermediates thereof | |
| US20010012900A1 (en) | 3-(1-hydroxy-pentylidene)-5-nitro-3H-benzofuran-2-one a process for the preparation thereof and the use thereof | |
| KR100364226B1 (en) | Method for preparing 7-halo-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro- [1.8] naphthyridine-3-carboxylate | |
| JP5088893B2 (en) | Method for producing piperidin-4-one derivative | |
| HK1033459B (en) | Intermediate compound for preparing sildenafil |